BioCentury
ARTICLE | Company News

Oncology Venture, Topotarget deal

November 19, 2012 8:00 AM UTC

Newco Oncology Venture debuted and acquired exclusive, worldwide rights from Topotarget to APO010, a recombinant fusion protein drug consisting of three human Fas ligands (TNF superfamily, member 6; ...